Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
CB1 receptor agonists
JWH-371
Другие языки:

    JWH-371

    Подписчиков: 0, рейтинг: 0
    JWH-371
    JWH-371.svg
    Legal status
    Legal status
    Identifiers
    • [5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
    PubChem CID
    ChemSpider
    Chemical and physical data
    Formula C30H33NO
    Molar mass 423.600 g·mol−1
    3D model (JSmol)
    • CCCCCN1C=C(C=C1C2=CC=C(C=C2)CCCC)C(=O)C3=CC=CC4=CC=CC=C43
    • InChI=1S/C30H33NO/c1-3-5-9-20-31-22-26(21-29(31)25-18-16-23(17-19-25)11-6-4-2)30(32)28-15-10-13-24-12-7-8-14-27(24)28/h7-8,10,12-19,21-22H,3-6,9,11,20H2,1-2H3 checkY
    • Key:PKNGYYSGLHBRGC-UHFFFAOYSA-N checkY

    JWH-371 ([5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 42 ± 1nM) and CB2 (Ki = 64 ± 2nM) receptors, binding ~1.5 times stronger to the CB1 receptor than the CB2 receptor. JWH-371 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.

    Legality

    In the United States JWH-371 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-371.

    In Canada, JWH-371 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.

    In the United Kingdom, JWH-371 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.

    See also



    Новое сообщение